title: Gene therapy strategies for hepatocellular carcinoma.
abstract: Hepatocellular carcinoma (HCC) is one of the most frequent cancers worldwide. Effective therapy to this cancer is currently lacking, creating an urgent need for new therapeutic strategies for HCC. Gene therapy approach that relies on the transduction of cells with genetic materials, such as apoptotic genes, suicide genes, genes coding for antiangiogenic factors or immunomodulatory molecules, small interfering RNA (siRNA), or oncolytic viral vectors, may provide a promising strategy. The aforementioned strategies have been largely evaluated in the animal models with HCC or liver metastasis. Due to the diversity of vectors and therapeutic genes, being used alone or in combination, gene therapy approach may generate great beneficial effects to control the growth of tumors within the liver.
authors.affiliation: Hepatitis Research Center, National Taiwan University Hospital and Graduate Institute of Microbiology, National Taiwan University College of Medicine, 7 Chung-Shan S. Road, Taipei 10016, Taiwan, R.O.C. lihhwa@ha.mc.ntu.edu.tw
authors.forename: Lih-Hwa
authors.initials: LH
authors.lastname: Hwang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D017209:Apoptosis / Q000502:physiology*; D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008113:Liver Neoplasms / Q000235:genetics / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods*; D011355:Prodrugs / Q000627:therapeutic use*; D034622:RNA Interference
chemical_list: D020533:Angiogenesis Inhibitors; D011355:Prodrugs